A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma

NCT05940441 · clinicaltrials.gov ↗

RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma

Interventions

DRUG: Capecitabine 500Mg Oral Tablet

Sponsor

Eye & ENT Hospital of Fudan University